Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 905711 with Chemotherapy in Advanced Gastrointestinal Cancers
NCT05087992Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2021
- Primary completion
- Oct 2023
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 1, randomised, open-label trial of BI 905711 in colorectal cancer (CRC) and pancreatic cancer (PC) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 35 days, Dose Limiting Toxicity up to 35 days and 2 more. Started Nov 2021; status: completed.
02
Drugs
BI 905711
03
Conditions
colorectal cancer (CRC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT05087992.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05087992.